PRINT - Finance - The Journal of Life Sciences

Capital Markets
Actavis’ $66B Purchase of Allergan Continues Record Year of M&A; Transactions for Life SciencesIncreasingly Competitive Environment for Sought-After Assets Pushes Prices Higher, Says Burrill Media. Read More.
Capital Markets
AbbVie Terminates Shire Acquisition, But M&A; Activity Remains BriskTotal life sciences transactions through first 10 months of 2014 reach $253.3 Billion, says Burrill Media Read More.
Capital Markets
U.S. Government’s Effort to Quell Tax-Driven Acquisitions Could Slow Life Sciences DealmakingNearly half of dollar volume of M&A; activity in 2014 involved inversions, says Burrill Media Read More.
Initial Public Offerings
Otonomy Raises $100M in Upsized IPOSeventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More.
Early-Stage Finance
Juno Therapeutics Fills Its Coffers with Another $134MFunding for the biotech startup in hot CAR T-cell therapy space tops $300 million. Read More.
Research and Development
Pharmas Tap Academia for Drug DiscoveryBristol-Myers teams with Allied Minds and Astellas teams with Cancer Research UK. Read More.
Initial Public Offerings
Biotech IPOs Keep on Coming But most end week at or below IPO price. Read More.
Initial Public Offerings
Five Life Sciences Companies Price IPOs below Target MidpointEnthusiasm wanes as the newly public biotechs trade flat or down out the gate. Read More.
Initial Public Offerings
Sage Therapeutics Scores $90M in Upsized IPO Strong demand raises confidence for more such deals. Read More.
Deals
AbbVie Inches Closer to Acquiring Shire Sweetened $53.6 billion offer gets UK biopharma to the negotiating table. Read More.
Initial Public Offerings
Two Biotechs Price IPOs Taking Deep HaircutsMinerva Neurosciences raises $32.7 million; GlobeImmune raises $15 million in discounted offerings. Read More.
Deals
Genentech Buys Seragon Pharmaceuticals for Up to $1.7BDeal is a coup for biotech’s founders, after selling sister company Aragon to J&J; last year. Read More.
Deals
Mersana and Merck KGaA in Licensing Deal Worth Up to $792M Partners will develop next-generation antibody drug conjugates against cancer. Read More.
Initial Public Offerings
Biotech IPOs Hit the MarketAfter an extended quiet period, seven companies raise half a billion in initial public offerings. Read More.
Mergers and Acquisitions
Merck Buys Idenix for $3.85BBig Pharma aims to take on Gilead in hepatitis C. Read More.

CAPITAL MARKETS:

Capital Markets

Capital Markets

Capital Markets

Initial Public Offerings

Early-Stage Finance

Research and Development

Initial Public Offerings

Initial Public Offerings

Initial Public Offerings

Deals

Initial Public Offerings

Deals

Deals

Initial Public Offerings

Mergers and Acquisitions